VILLEPINTE

Guerbet: CHMP positive opinion

Retrieved on: 
Thursday, October 12, 2023
III, European, European Commission, Committee for Medicinal Products for Human Use, CHMP, Radiology, Agent handling, Brain, Breast, Pancreas, Medicine, Central nervous system, Liver, Magnetic resonance imaging, European Medicines Agency, Spine, EMA, FDA, Kidney, Committee, Lung, Human, MRI, Tissue, Civil service commission, CNS, Prostate, Gadolinium, Patient, Regulatory affairs, Medical imaging, Health, EU

Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.

Key Points: 
  • Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.
  • Villepinte, France, 12 october 2023: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the granting of a marketing authorisation for Elucirem™ (Gadopiclenol) in the European Union (EU) for use in adults and children aged 2 years and over for MRI with contrast enhancement.
  • The positive opinion from the CHMP is essentially based on data from two phase III clinical trials completed in March 2021.
  • "This positive opinion from the CHMP,
    at the end of 2023, will bring European patients and health professionals

Guerbet: 2023 half-year results

Retrieved on: 
Wednesday, September 20, 2023
Tax, CER, Bank statement, European Directive on Traditional Herbal Medicinal Products, Agent handling, WCR, Committee, MRI, Guerbet, EBITDA, Algorithm, Artificial intelligence, Depreciation, Growth, Liver, Committee for Medicinal Products for Human Use, Iodine, Disease, CHMP, Cryptocurrency

As indicated when the annual results were published, Guerbet's 2023 operational profitability is subject to a context in which costs are rising more sharply than in the previous fiscal year.

Key Points: 
  • As indicated when the annual results were published, Guerbet's 2023 operational profitability is subject to a context in which costs are rising more sharply than in the previous fiscal year.
  • As of 30 June 2023, the Group's operating income was €10.3 million, compared to €16.9 million one year earlier.
  • In terms of profitability, inflationary pressures (in particular for iodine) will continue to be felt in the second half of 2023.
  • In this context, Guerbet confirms that it anticipates revenue growth of more than 5% on a like-for-like basis and at CER in 2023.

Guerbet: First-half 2023 revenue

Retrieved on: 
Thursday, July 20, 2023
Acceleration, Face, CER, Marketing, Prostate, MRI, Guerbet, Medical imaging, EBITDA, Acquisition, Algorithm, Artificial intelligence, Liver, Growth, ESG, Iodine, AI, Security (finance), Rare-earth element

Diagnostic Imaging revenue in the first half of 2023 increased 3.3% at CER (+2.5% at current exchange rates).

Key Points: 
  • Diagnostic Imaging revenue in the first half of 2023 increased 3.3% at CER (+2.5% at current exchange rates).
  • It should be noted that X-ray revenue now includes the revenue of the company Intrasense, consolidated as of January 2023.
  • Intrasense (€3.8 million in revenue in 2022) joined the Group to accelerate its strategy for marketing AI technologies from third parties.
  • Overall, and as indicated in the reporting of full-year results in March, revenue growth in the second half of 2023 is expected to be stronger than in the first half.

Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

Retrieved on: 
Monday, July 17, 2023
Medical imaging, Database, Male, Secretary of State for Universities, Research, Development and Innovation, Senior, Marketing, European Association of Urology, Agent handling, Cancer, Magnetic resonance imaging, Intelligence, Innovation, Prostate, Radiological Society of North America, Radiology, Development, Death, MRI, Patient, Urology, Algorithm, Annual general meeting, Neoplasm, Deep learning, GBT, Artificial intelligence, Diagnosis, Digital, WHO, RSNA, Disease, MIDL, Biopsy, Prostate cancer, Pharmaceutical industry, Guerbet, Research

The second male cancer according to the WHO, prostate cancer, with 1.4 million new cases each year worldwide, accounts for 6.8% of male cancer-related deaths (350,000 deaths per year).

Key Points: 
  • The second male cancer according to the WHO, prostate cancer, with 1.4 million new cases each year worldwide, accounts for 6.8% of male cancer-related deaths (350,000 deaths per year).
  • Magnetic resonance imaging (MRI) plays an increasingly important role in the early diagnosis of prostate cancer.
  • By training artificial intelligence on these data, it becomes possible to create a model capable of detecting the early signs of prostate cancer.
  • The PI-CAI Grand Challenge, launched in November 2022 on the detection of prostate cancer, aims to encourage technological advances in early diagnosis and accurate detection of prostate cancer and to evaluate the performance of participants' artificial intelligence algorithms.

Guerbet: Q1 2023 Revenue

Retrieved on: 
Thursday, April 20, 2023
Medical imaging, CER

Diagnostic Imaging revenue was down 1.0% at CER in Q1 2023.

Key Points: 
  • Diagnostic Imaging revenue was down 1.0% at CER in Q1 2023.
  • X-ray revenue at CER was down 1.9%, reflecting lower volumes of Optiray® (impact of production delays at Raleigh), while sales of Xenetix® (+17.7%) and injection solutions (+9.5%) remained very strong.
  • In Interventional Imaging, activity was down 3.8% at CER from the same period of the previous fiscal year because a large order in the United States was postponed to Q2 2023.
  • For the current fiscal year, revenue growth is expected to exceed 5% on a like-for-like basis and at CER.

Guerbet: 2022 annual results

Retrieved on: 
Wednesday, March 22, 2023
Acceleration, Pressure, IBM, Intervention, CER, IBM Watson, Bank statement, Software, Agent handling, WCR, Mass meeting, MRI, Medical imaging, EBITDA, Artificial intelligence, Depreciation, Growth, Environment, Cryptocurrency, Holding company, Fine chemical, Iodine, Merative

In 2022, Guerbet managed to preserve its operational profitability by demonstrating great financial discipline to compensate for the impact of high inflation on certain costs.

Key Points: 
  • In 2022, Guerbet managed to preserve its operational profitability by demonstrating great financial discipline to compensate for the impact of high inflation on certain costs.
  • Its reported rate was 13.7% of revenue in 2022, compared with 14.4% in the previous year.
  • As of December 31, 2022, the Group’s operating result was negative at -€18.2 million, a change entirely due to items with no impact on cash flow.
  • Certain inflationary effects, with little impact in 2022, will have a significant negative effect on the Group’s margins in 2023.

Guerbet: 2022 revenue

Retrieved on: 
Thursday, February 9, 2023
Software, Diagnosis, Medical imaging, MRI, Iodine, Intelligence, EBITDA, CER, Guerbet, Watson (computer), Therapy, Acceleration, Pharmaceutical industry

Annual revenue in Diagnostic Imaging was up 1.7% at current exchange rates and down -2.2% at CER.

Key Points: 
  • Annual revenue in Diagnostic Imaging was up 1.7% at current exchange rates and down -2.2% at CER.
  • X-ray activity declined -4.4% at CER in 2022 due to the lower revenue from Optiray®.
  • Confirmation of the 2022 profitability target, acceleration of activity in 2023
    For 2022, despite the revenue shortfall associated with the temporary drop in production in Raleigh, Guerbet confirmed its ability to generate an EBITDA margin of between 13% and 14%, excluding extraordinary costs from the optimization of the Group’s operating structure and changes in the sales model in China.
  • Its revenue growth target for this year is above 5% on a like-for-like basis and at constant exchange rates.

Guerbet: 2023 Strategic Priorities

Retrieved on: 
Monday, January 16, 2023
Prostate cancer, European Medicines Agency, Algorithm, Face, HSG, Hysterosalpingography, Liver, X-ray, Environment, Watson (computer), Microparticle, Research, Google Images, Lymphogram, IBM Watson Health, Intellectual property, Iodine, Growth, Lipiodol, Intelligence, Liver cancer, MRI, Investment, Acquisition, EMA, Risk management, Medical imaging, Guerbet, Mer (software distribution)

Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Key Points: 
  • Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
  • In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
  • Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
  • Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.

Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

Retrieved on: 
Thursday, November 3, 2022
Research, RSNA, AI, Communication, GBT, BPI, ECR, Artificial intelligence, Mer (software distribution), Pancreatic cancer, Intelligence, Partnership, Euronext Paris, Prostate cancer, Program, Solution, Guerbet

Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018.

Key Points: 
  • Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018.
  • This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers.
  • The termination follows Merative's strategic shift in how it delivers artificial intelligence within its imaging product portfolio.The new Asset Assignment and License Agreement grants Guerbet the ability and autonomy to pursue research and development, and plan for the market launch of Artificial Intelligence solutions.
  • Assets developed during the partnership, including source code for application software, Artificial Intelligence algorithms and the associated intellectual property, are being transferred to Guerbet.

Guerbet: Revenue at September 30, 2022

Retrieved on: 
Thursday, October 20, 2022
European Medicines Agency, AMF, GBT, Acceleration, US Foods, Euronext Paris, Research, MRI, Food, AI, Group, CER, Forward-looking statement, Agent handling, MA, Medical imaging, Solution, Security (finance), Pharmaceutical industry, Risk management, Guerbet

Revenue from Diagnostic Imaging increased by 0.5% at CER over the first 9 months, with a Q3 up 4.3% compared with the same period in 2021.

Key Points: 
  • Revenue from Diagnostic Imaging increased by 0.5% at CER over the first 9 months, with a Q3 up 4.3% compared with the same period in 2021.
  • X-Ray revenue at CER decreased by 2.2% at 9 months and 3.1% in Q3 in the wake of the decrease in Optiray sales, while Xenetix sales remained very steady.
  • Against this backdrop, the Group expects 2022 revenue growth to be less than 2% on a like-for-like basis and at constant exchange rates compared with a previously announced range of 2% to 4%.
  • Guerbet (GBT) is listed on Euronext Paris (segment Bmid caps) and generated 732million in revenue in 2021.